Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Open-label (Part 1), Randomized (Part 2), Phase I/IIa Trial to Study Safety and Tolerability of Multiple Rising Intravitreal Doses of BI 3812465 in Patients With Center-involved Diabetic Macular Edema

NCT07553429 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07553429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07553429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Open-label (Part 1), Randomized (Part 2), Phase I/IIa Trial to Study Safety and Tolerability of Multiple Rising Intravitreal Doses of BI 3812465 in Patients With Center-involved Diabetic Macular Edema
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 14, 2026
Completion date
July 6, 2027
Enrollment
49 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema